PUBLICATIONS
Therapies With No Compromise
| Platform | Publication | Year | Link |
|---|---|---|---|
| ESMO, Madrid | First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors | 2026 | View publication |
| ASCO, Chicago | Phase Ia dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors | 2025 | View publication |
| ESMO TAT, Paris | RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models | 2023 | View publication |
| ESMO, Paris | Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC) | 2022 | View publication |
Archive notice: information reflects the date of publication.
